Wadsworth Center Joins NGD Cefiderocol Data Consortium

Next Gen Diagnostics (NGD) has announced the inclusion of the Wadsworth Center, the public health laboratory of the New York State Department of Health, into the NGD Cefiderocol Data Consortium. This partnership aims to develop sequencing-based diagnostic tools to determine resistance to cefiderocol, a novel antibiotic introduced by Shionogi after three decades.

Carbapenem-resistant infections are a growing concern, particularly in New York. Cefiderocol offers hope for cases resistant to current last-resort antibiotics. The difficulty of testing cefiderocol resistance in vitro makes a sequence-based method crucial.

NGD’s collaboration with Shionogi and the global consortium reflects the broader challenge of antibiotic resistance. Leveraging NGD's validated machine learning models and bioinformatics, this initiative seeks to enhance understanding of resistance mechanisms.